BlueWind Medical, Ltd., a leader in Implantable Tibial Neuromodulation (ITNM) and developer of the Revi® System, a patient-centric solution for urgency urinary incontinence (UUI), today announced the close of $47.8 million in financing through a combination of equity and debt.

BlueWind Medical, Ltd. 是植入式胫神经调节 (ITNM) 领域的领导者，同时也是以患者为中心的急迫性尿失禁 (UUI) 解决方案 Revi® 系统的开发者，该公司今天宣布通过股权和债务组合完成了 4780 万美元的融资。

Proceeds from the financing will be used to further commercialization efforts for the Revi® System, including the continued expansion of the company's commercial sales organization and ongoing investment in market access initiatives that broaden patient and provider access to the therapy.

融资所得将用于进一步推动Revi®系统的商业化工作，包括持续扩展公司的商业销售团队，并继续投资于扩大患者和医疗服务提供者获得该疗法的市场准入计划。

'Urgency urinary incontinence affects millions of people, creating a significant need for effective, durable treatment options that fit seamlessly into patients’ lives,' said Kerry Nelson, Chief Executive Officer of BlueWind Medical. 'This financing reflects deep conviction in our team, our technology, and the opportunity ahead to establish Revi as the new standard of care.'.

“紧迫性尿失禁影响着数百万人，这使得对能够无缝融入患者生活的有效且持久的治疗方案产生了重大需求，”BlueWind Medical首席执行官凯里·纳尔逊表示。“此次融资充分体现了对我们团队、我们的技术以及未来将Revi确立为护理新标准的机会的深切信心。”

The financing builds on a series of clinical achievements over the past year, including three-year results from the pivotal OASIS study that confirmed Revi's sustained efficacy, excellent safety, and 95% patient satisfaction at 36 months.1

这笔融资建立在过去一年的一系列临床成果之上，其中包括关键的OASIS研究的三年结果，证实了Revi在36个月时持续的有效性、极佳的安全性以及95%的患者满意度。1

'This financing is an important milestone for BlueWind and a strong validation of the progress we are making as a leader in Implantable Tibial Neuromodulation for urgency urinary incontinence,' said Stephen Armstrong, Chief Financial Officer of BlueWind Medical. 'The capital allows us to scale our commercial organization, expand market access, and ensure that more patients and providers can benefit from a clinically proven, patient-centric therapy.

“此次融资是BlueWind的重要里程碑，也是对我们作为治疗急迫性尿失禁的植入式胫骨神经调节领域的领导者所取得进展的有力验证，”BlueWind Medical首席财务官Stephen Armstrong表示。“这笔资金使我们能够扩大商业团队规模、拓展市场准入，并确保更多患者和医疗服务提供者能够受益于经过临床验证的、以患者为中心的疗法。”

We are grateful for the continued confidence of our investors as we execute on the next phase of our growth.'.

“在我们执行增长的下一阶段时，我们对投资者持续的信任表示感激。”

About the Revi® System

关于Revi®系统

Revi® is an innovative Implantable Tibial Neuromodulation (ITNM) device designed for the treatment of urgency urinary incontinence (UUI). Implanted near the ankle in a single outpatient procedure under local anesthesia, Revi delivers targeted stimulation to the posterior tibial nerve via a lightweight, external wearable.

Revi® 是一种创新的可植入胫神经调节（ITNM）设备，用于治疗急迫性尿失禁（UUI）。在局部麻醉下通过单次门诊手术将 Revi 植入踝关节附近，然后通过轻便的外部可穿戴设备向胫后神经提供靶向刺激。

This design offers patients a simple, durable, and effective long-term solution for UUI symptom relief. Patients activate therapy once daily at home, without the need for internal batteries or leads, avoiding complications such as lead fracture, migration, or battery depletion..

该设计为患者提供了一种简单、耐用且有效的长期解决方案，以缓解UUI症状。患者每天在家中激活治疗一次，无需内部电池或导线，避免了导线断裂、移位或电池耗尽等并发症。

About BlueWind Medical Ltd.

关于BlueWind Medical Ltd.

BlueWind Medical is transforming the field of neuromodulation therapy through the development of innovative, patient-centric medical technology for the treatment of disease. BlueWind is committed to enhancing the quality of life and overall well-being of patients with an initial focus on those living with urgency urinary incontinence (UUI).

BlueWind Medical 通过开发创新的、以患者为中心的医疗技术，正在变革神经调节治疗领域，用于治疗疾病。BlueWind 致力于提高患者的生活质量和整体福祉，最初专注于治疗急迫性尿失禁 (UUI) 的患者。

BlueWind’s Revi® System is the first and only Implantable Tibial Neuromodulation (ITNM) device activated by a battery-operated external wearable to receive FDA clearance for the treatment of patients with UUI. For additional information about BlueWind Medical, please visit bluewindmedical.com..

BlueWind的Revi®系统是首个也是唯一一个通过电池供电的外部可穿戴设备激活的植入式胫神经调节（ITNM）装置，已获得FDA批准用于治疗UUI患者。如需更多关于BlueWind Medical的信息，请访问bluewindmedical.com。

1 Amundsen CL, Sutherland SE, Heesakkers JPFA, Toozs-Hobson P, Martens F, McCrery RJ, et al. Three-Year Efficacy and Safety of Revi Implantable Tibial Neuromodulation from the Pivotal OASIS Study. Journal of Urology. 2026 April; 0(0): https://doi.org/10.1097/JU.0000000000005062

1 阿蒙森 CL，苏瑟兰 SE，希萨克尔斯 JPFA，图兹-霍布森 P，马滕斯 F，麦克雷里 RJ，等。来自关键性OASIS研究的Revi植入式胫神经调节三年疗效与安全性。《泌尿学杂志》。2026年4月；0(0): https://doi.org/10.1097/JU.0000000000005062

Contacts

联系人

Media Contact:

媒体联系人：

Isabel Chowdhury

伊莎贝尔·乔杜里

Supreme Communications

最高通信

isabel.chowdhury@supremecomms.ai

伊莎贝尔·乔杜里@supremecomms.ai